Type 2 diabetes mellitus (T2DM) is one of the greatest health crises of our time and its
prevalence is projected to increase by> 50% globally by 2045. Currently, 10 classes of …

Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global
epidemic. In order to achieve optimal glucose control, it is often necessary to rely on …

Sulphonylureas have been commercially available since the 1950s, but their use continues
to be associated with controversy. Although adverse cardiovascular outcomes in some …

There is a limited understanding of how genetic loci associated with glycemic traits and type
2 diabetes (T2D) influence the response to antidiabetic medications. Polygenic scores …

Patients with myocardial ischemic diseases or who are undergoing one of various heart
treatments, such as open heart surgery, coronary artery bypass grafting, percutaneous …

Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of
diabetes where defining the genetic cause has a dramatic impact on treatment—with …

Aims/hypothesis Characterisation of genetic variation that influences the response to
glucose-lowering medications is instrumental to precision medicine for treatment of type 2 …

Polymorphism in cytochrome P450 (CYP) 2C9 enzyme is known to cause significant inter-
individual differences in drug response and occurrence of adverse drug reactions. Different …

Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic
response to 6 month treatment with DPP4 inhibitors. Patients & methods: 206 patients with …

Investigators of previous cross-sectional epigenome-wide association studies (EWAS) in
adults have reported hundreds of 5′-cytosine-phosphate-guanine-3′(CpG) sites …